CN108578606A - Treat the Chinese medicine preparation of rheumatoid arthritis - Google Patents

Treat the Chinese medicine preparation of rheumatoid arthritis Download PDF

Info

Publication number
CN108578606A
CN108578606A CN201810865992.2A CN201810865992A CN108578606A CN 108578606 A CN108578606 A CN 108578606A CN 201810865992 A CN201810865992 A CN 201810865992A CN 108578606 A CN108578606 A CN 108578606A
Authority
CN
China
Prior art keywords
group
radix
present
rheumatoid arthritis
chinese medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810865992.2A
Other languages
Chinese (zh)
Other versions
CN108578606B (en
Inventor
王青山
白长川
张琳
侯丽艳
肖楠
何世勇
黄瑞雪
薛崇祥
乔艳皊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian Medical University
Original Assignee
Dalian Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian Medical University filed Critical Dalian Medical University
Priority to CN201810865992.2A priority Critical patent/CN108578606B/en
Publication of CN108578606A publication Critical patent/CN108578606A/en
Application granted granted Critical
Publication of CN108578606B publication Critical patent/CN108578606B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/237—Notopterygium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/238—Saposhnikovia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A61K36/515—Gentiana
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/714—Aconitum (monkshood)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention discloses a kind of Chinese medicine preparation for treating rheumatoid arthritis, is for Chinese traditional medicine water extract for oral administration, the Chinese medicine and mass ratio are as follows：Radix Astragali 35, cassia twig 15, stir-baked RADIX PAEONIAE ALBA 25, Radix Aconiti Lateralis Preparata 10, Radix Angelicae Sinensis 15, coix seed 25, windproof 15, bark of ash 15, Rhizoma Et Radix Notopterygii 10, Rhizoma Chuanxiong 10, rhizoma atractylodis 15, Radix Glycyrrhizae 15.The present invention treats Small side effects caused by rheumatoid arthritis, by being detected to RF, TNF α, IL 6,10 contents of IL in the mouse Articular swelling and serum after treatment, the results showed that the effect of present invention is to rheumatoid arthritis is better than the prior art.

Description

Treat the Chinese medicine preparation of rheumatoid arthritis
Technical field
The present invention relates to a kind of Chinese medicine preparation, especially a kind of Small side effects, eutherapeutic treatment rheumatoid arthritis Chinese medicine preparation.
Background technology
Rheumatoid arthritis（RA）It is a kind of general immunity arthritis, is one of the chronic disease for seriously threatening health. It is mainly characterized by chronic, symmetry, progressive and invasion, the arthroncus deformation being embodied in caused by arthrosynovitis And osteoclasia, notably disable.The cause of disease and pathogenesis of RA not yet illustrates, and inflammatory change is its typical pathological change, is immunized The progress that system and synovial tissue's cell and its cell factor of secretion aggravate disease.In recent years, domestic and foreign scholars are according to evidence-based Medical evidence proposes that the therapeutic purpose of RA is so that patient is reached remission state as early as possible and remain steady in a long-term.Clinically RA is normal The medicine seen is divided into three categories：Non-steroid anti-inflammatory drug（NSAIDS）, glucocorticoid（GCS）And improve the wind resistance of the state of an illness Wet medicine（DMARDS）.Methotrexate (MTX)（MTX）For antirheumatic drug（DMARDS）Choice drug,
But the constitutional symptoms such as weak, fever can be brought, epigastric discomfort is lost the appetite, and oral cavity ulceration, hemorrhage of digestive tract etc. disappears Change road symptom, the adverse reactions such as three system of haemocyte reduction.Said medicine is often because curative effect does not comply with one's wishes or toxic side effect is larger and difficult To promote or be used for a long time.RA belongs to the scope of " bi Zheng ", Huangqi Guizhi Wuwu Tang in Chinese medicine（Radix Astragali, cassia twig, Chinese herbaceous peony, life Ginger and jujube）Or Guizhi-Shoyao-Zhimu Decoction（Cassia twig, Chinese herbaceous peony, Radix Glycyrrhizae, Chinese ephedra, ginger, Rhizoma Atractylodis Macrocephalae, rhizoma anemarrhenae, windproof and Radix Aconiti Lateralis Preparata）For More famous compound, Small side effects, but therapeutic effect is not very ideal.
Invention content
The present invention is to provide a kind of Small side effects, good effect to solve the above-mentioned technical problem present in the prior art Treatment rheumatoid arthritis Chinese medicine preparation.
Technical solution of the invention is：A kind of Chinese medicine preparation for treating rheumatoid arthritis, it is characterised in that be to use In Chinese traditional medicine water extract for oral administration, the Chinese medicine and mass ratio are as follows：Radix Astragali 35, cassia twig 15, stir-baked RADIX PAEONIAE ALBA 25, Radix Aconiti Lateralis Preparata 10, Radix Angelicae Sinensis 15, coix seed 25, windproof 15, bark of ash 15, Rhizoma Et Radix Notopterygii 10, Rhizoma Chuanxiong 10, rhizoma atractylodis 15, Radix Glycyrrhizae 15.
Herbal toxic effect used in the present invention is small, by RF, TNF in the mouse Articular swelling and serum after treatment α, IL-6, IL-10 content are detected, the results showed that the effect of present invention is to rheumatoid arthritis is better than the prior art.
Specific implementation mode
The Chinese medicine preparation of the treatment rheumatoid arthritis of the present invention, be for Chinese traditional medicine water extract for oral administration, the Chinese medicine and Quality is as follows：Radix Astragali 35g, cassia twig 15g, stir-baked RADIX PAEONIAE ALBA 25g, Radix Aconiti Lateralis Preparata 10g, Radix Angelicae Sinensis 15g, coix seed 25g, windproof 15g, bark of ash 15g, Rhizoma Et Radix Notopterygii 10g, Rhizoma Chuanxiong 10g, rhizoma atractylodis 15g, Radix Glycyrrhizae 15g.
Preparation method is first by the independent decocting 30min of Radix Aconiti Lateralis Preparata, remaining Chinese medicine adds 10 times of distilled waters to impregnate 30min, pours into It in Radix Aconiti Lateralis Preparata decocting liquid, boils by intense fire, is adjusted to be cooked by slow fire 2h, poured into container after concoction cooling.Add 8 times into the dregs of a decoction again Distilled water boils by intense fire, is adjusted to be cooked by slow fire 2h, then concoction is poured into container, i.e., gained concoction will mix twice.Later will The extracting solution that proportion is 4g/mL is made in being concentrated on Rotary Evaporators in concoction in container.
Experiment：
1. grouping
80 200 ± 20g SD rats adaptable feds 1 week, are randomly divided into 8 groups, blank group 10, model group 10, positive drug Group 10, low dose group of the embodiment of the present invention 10, middle dosage of the embodiment of the present invention 10, high dose group of the embodiment of the present invention 10 Only, Huangqi Guizhi Wuwu Tang group 10, Guizhi-Shoyao-Zhimu Decoction group 10.
It is prepared by rat rheumatoid arthritis model
With reference to the modeling method of Freund, 10% chloraldurate of SD rats（0.3ml/100g）After abdominal cavity holonarcosis（Without blink It is painless to pinch foot for reaction）, 75% alcohol disinfecting of right toes, in addition to blank group rat, the subcutaneous multiple spot note of remaining group rat Complete Freund's adjuvant 0.2mL is penetrated, injection 0.1mL complete Freund's adjuvant booster immunizations are primary after 1 week, and arthritis is carried out after two weeks Scoring is 4 points；Blank group rat injects normal saline.
3. prepared by medicament
Huangqi Guizhi Wuwu Tang：By Radix Astragali（15g）, cassia twig（12g）, Chinese herbaceous peony（12g）, ginger（25g）, 4 pieces of ratio structures of jujube At.The same embodiment of the present invention of extraction process, is made 4g/mL extracting solutions.
Guizhi-Shoyao-Zhimu Decoction：By cassia twig（12g）, Chinese herbaceous peony（9g）, Radix Glycyrrhizae（6g）, Chinese ephedra（12g）, ginger（15g）, Rhizoma Atractylodis Macrocephalae （15g）, rhizoma anemarrhenae（12g）, it is windproof（12g）, Radix Aconiti Lateralis Preparata（10g）Composition of proportions.The same embodiment of the present invention of extraction process, is made 4g/ ML extracting solutions.
4. administration
Normal group and model group give the physiological saline of therapeutic dose after 24 h of modeling；Positive drug group methotrexate (MTX) physiology Brine configures, ultrasonic dissolution, and administration concentration is 0.1 mg/mL, and dosage is 1 mg/kg；The embodiment of the present invention is basic, normal, high Dosage group gives the embodiment of the present invention, and dosage is respectively 10 g/kg, 20 g/kg, 40 g/kg；Huangqi Guizhi Wuwu Tang group Dosage is 40 g/kg；Guizhi-Shoyao-Zhimu Decoction group dosage is 40g/kg.Every group is administered once a day, successive administration 5 Week.
5. detection
Vernier caliper measurement Articular swelling is used after modeling weekly, calculate and records Articular swelling increase percentage.It calculates public Formula be Articular swelling increase percentage=（Minute point joint diameter-initial diameter）/ initial diameter × 100%.In last Rat blood serum is taken after administration, and RF, TNF α, IL-6, IL-10, IL-1 β content in serum are detected using enzyme-linked immunization, Specific detecting step, method are operated by kit specification.
6. statistical method
All data are calculated using SPSS16.0 softwares, measurement data mean ± standard deviationIt indicates, between group Compare and uses independent sampletIt examines,p≤ 0.05 has statistical significance.
7. result
7.1 Articular swelling results such as table 1-1, table 1-2.
Table 1-1
Table 1-2
*P<0.05, **P<0.01, compared with model group；#P<0.05, ##P<0.01, compared with blank group.
As a result it shows：Each point in time, blank control group and the significant difference of model group illustrate modeling success.From Start within three weeks, positive drug group and the significant difference of model group, illustrates that methotrexate (MTX) has therapeutic effect.From 4th week, this Inventive embodiments administration group, than significant difference, illustrates that the embodiment of the present invention there is treatment to make rheumatoid with model group With.From 4th week, Huangqi Guizhi Wuwu Tang group and Guizhi-Shoyao-Zhimu Decoction group and model group ratio are statistically significant, illustrate Huang Five object soup of stilbene cassia twig and Guizhi-Shoyao-Zhimu Decoction have therapeutic effect to rheumatoid arthritis, while can be seen that the present invention is implemented Example curative effect is better than positive drug group, Huangqi Guizhi Wuwu Tang group and Guizhi-Shoyao-Zhimu Decoction group.
RF, TNF α, IL-6, IL-10 content detection result such as table 2-1, table 2-2 in 7.2 serum
Table 2-1
Table 2-2
*P<0.05, **P<0.01, compared with model group；#P<0.05, ##P<0.01, compared with blank group.
The result shows that：
① RF：Blank group and model group ratio are statistically significant, prompt modeling success；Positive drug group and model group, blank group ratio It is statistically significant, make RF close to normal level, prompts methotrexate (MTX) that there is therapeutic effect.Low dose group of the embodiment of the present invention It is statistically significant with model group, positive drug group ratio, it prompts low dosage of the embodiment of the present invention to have and alleviates rheumatoid arthritis Effect.Middle dose group of the embodiment of the present invention with model group than statistically significant, it is not statistically significant with positive drug group, prompt Middle dosage of the embodiment of the present invention has therapeutic effect to rheumatoid arthritis.High dose group of the embodiment of the present invention and model group, sun Property medicine group ratio it is statistically significant, and make RF closer to normal level, prompt high-dose therapy effect of the embodiment of the present invention excellent In methotrexate (MTX).Huangqi Guizhi Wuwu Tang group and Guizhi-Shoyao-Zhimu Decoction group and model group ratio are statistically significant, prompt Radix Astragali Five object soup of cassia twig and Guizhi-Shoyao-Zhimu Decoction have therapeutic effect to rheumatoid arthritis, but therapeutic effect is only better than the present invention Embodiment low dose group is not so good as high dose group of the embodiment of the present invention.
② TNFα：Blank group and model group ratio are statistically significant, prompt modeling success；Positive drug group and model group ratio Statistically significant, with blank group than not statistically significant, prompt methotrexate (MTX) has fabulous therapeutic effect.The present invention is implemented Example low dose group and model group, positive drug group ratio are statistically significant, prompt low dosage of the embodiment of the present invention to have and alleviate class The effect of rheumathritis.Middle dose group of the embodiment of the present invention is with model group, positive drug group than statistically significant, and prompt is originally Inventive embodiments middle dosage has therapeutic effect to rheumatoid arthritis.High dose group of the embodiment of the present invention and model group, the positive Medicine group ratio is statistically significant, and makes TNF α close to normal level, and high dose of the embodiment of the present invention is prompted to have therapeutic effect. Huangqi Guizhi Wuwu Tang group and Guizhi-Shoyao-Zhimu Decoction group and model group ratio are statistically significant, prompt Huangqi Guizhi Wuwu Tang and Guizhi-Shoyao-Zhimu Decoction has a therapeutic effect to rheumatoid arthritis, but the therapeutic effect and embodiment of the present invention is low, middle dosage Group effect is suitable, is not so good as high dose group of the embodiment of the present invention.
③ IL-6：Blank group and model group ratio are statistically significant, prompt modeling success；Positive drug group and model group, sky White group ratio is statistically significant, makes IL-6 close to normal level, methotrexate (MTX) is prompted to have therapeutic effect.The embodiment of the present invention Low dose group is not statistically significant with model group, and low dosage of the embodiment of the present invention is prompted not have therapeutic effect.The embodiment of the present invention Middle dose group and model group, positive drug group ratio are statistically significant, prompt middle dosage of the embodiment of the present invention to rheumatoid arthrosis Inflammation has therapeutic effect, but therapeutic effect unobvious.High dose group of the embodiment of the present invention and model group are statistically significant, with sun Property medicine group it is not statistically significant, make IL-6 close to normal level, prompt high dose of the embodiment of the present invention that there is treatment rheumatoid to close Save scorching effect.Huangqi Guizhi Wuwu Tang group and Guizhi-Shoyao-Zhimu Decoction group and model group ratio are statistically significant, prompt Radix Astragali Five object soup of cassia twig and Guizhi-Shoyao-Zhimu Decoction have therapeutic effect to rheumatoid arthritis, but therapeutic effect and the present invention are implemented Example middle dose group is suitable, is not so good as high dose group of the embodiment of the present invention.
④ IL-10：Blank group and model group ratio are statistically significant, prompt modeling success；Positive drug group and model group, Blank group ratio is statistically significant, makes IL-10 close to normal level, methotrexate (MTX) is prompted to have therapeutic effect.The present invention is real It is statistically significant with model group to apply a low dose group, prompts low dosage of the embodiment of the present invention invalid to rheumatoid arthritis.This Inventive embodiments middle dose group and model group, positive drug group ratio are statistically significant, prompt middle dosage pair of the embodiment of the present invention Rheumatoid arthritis has therapeutic effect, but therapeutic effect unobvious.High dose group of the embodiment of the present invention and model group, positive drug Group ratio is statistically significant, and high dose of the embodiment of the present invention is prompted to have therapeutic effect to rheumatoid arthritis.Radix Astragali cassia twig Five object soup groups and Guizhi-Shoyao-Zhimu Decoction group and model group ratio are statistically significant, prompt Huangqi Guizhi Wuwu Tang and cassia twig Chinese herbaceous peony Anemarrhenae Decoction has therapeutic effect to rheumatoid arthritis, but therapeutic effect and middle dose group of the embodiment of the present invention are suitable, are not so good as High dose group of the embodiment of the present invention.

Claims (1)

1. a kind of Chinese medicine preparation for treating rheumatoid arthritis, it is characterised in that be for Chinese traditional medicine water extract for oral administration, in described Medicine and mass ratio are as follows：Radix Astragali 35, cassia twig 15, stir-baked RADIX PAEONIAE ALBA 25, Radix Aconiti Lateralis Preparata 10, Radix Angelicae Sinensis 15, coix seed 25, windproof 15, bark of ash 15, Rhizoma Et Radix Notopterygii 10, Rhizoma Chuanxiong 10, rhizoma atractylodis 15, Radix Glycyrrhizae 15.
CN201810865992.2A 2018-08-01 2018-08-01 Traditional Chinese medicine preparation for treating rheumatoid arthritis Active CN108578606B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810865992.2A CN108578606B (en) 2018-08-01 2018-08-01 Traditional Chinese medicine preparation for treating rheumatoid arthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810865992.2A CN108578606B (en) 2018-08-01 2018-08-01 Traditional Chinese medicine preparation for treating rheumatoid arthritis

Publications (2)

Publication Number Publication Date
CN108578606A true CN108578606A (en) 2018-09-28
CN108578606B CN108578606B (en) 2021-02-19

Family

ID=63619053

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810865992.2A Active CN108578606B (en) 2018-08-01 2018-08-01 Traditional Chinese medicine preparation for treating rheumatoid arthritis

Country Status (1)

Country Link
CN (1) CN108578606B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113134064A (en) * 2021-04-27 2021-07-20 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Composition for preventing rheumatoid arthritis and preparation method and application thereof
CN115814048A (en) * 2022-12-09 2023-03-21 北京马家一绝中医风湿骨病研究院 Chinese medicine for treating rheumatism and its preparation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113134064A (en) * 2021-04-27 2021-07-20 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Composition for preventing rheumatoid arthritis and preparation method and application thereof
CN115814048A (en) * 2022-12-09 2023-03-21 北京马家一绝中医风湿骨病研究院 Chinese medicine for treating rheumatism and its preparation

Also Published As

Publication number Publication date
CN108578606B (en) 2021-02-19

Similar Documents

Publication Publication Date Title
CN104367911A (en) Traditional Chinese medicinal composition for treating rheumatic arthritis and rheumatoid arthritis and preparation method thereof
CN104353047A (en) Traditional Chinese medicine for treating nephritis
CN104383055A (en) Drug for treating end-stage liver diseases caused by chronic hepatitis B and preparation method of drug
CN102988672A (en) Traditional Chinese medicine composition for treating irregular menstruation
CN103705797B (en) A kind of medicine for the treatment of renal calculus
CN101011544A (en) Gout rapid recovery pill(capsule) and preparation technique thereof
CN101991752A (en) Traditional Chinese medicine formula for treating gout
CN108578606A (en) Treat the Chinese medicine preparation of rheumatoid arthritis
CN113713039A (en) Traditional Chinese medicine composition for treating membranous nephropathy and application thereof
CN103860659A (en) Traditional Chinese medicine for treating early nephrolith
CN104027684A (en) Traditional Chinese medicinal composition for treating gout and preparation method thereof
CN103933513A (en) Traditional Chinese medicine composition for removing acnes
CN103432330B (en) Traditional Chinese medicine used for treating renal failure and preparation method thereof
CN103100003B (en) Traditional Chinese medicine composition for treating acute gouty arthritis
CN101703738B (en) Chinese medicament for treating gastritis and gastric ulcer
CN103211994B (en) Chinese medicament for treating chronic diarrhea
CN105535367A (en) Traditional Chinese medicine for treating kidney-deficiency type hypomenorrhea
CN104491800A (en) Traditional Chinese medicine composition for treating chronic colitis
CN115137785B (en) Membranous kidney prescription for treating idiopathic membranous nephropathy
CN101590208A (en) A kind of pharmaceutical composition for the treatment of rheumatoid arthritis and preparation method thereof
CN103705646B (en) A kind of Chinese medicinal enema treating ulcerative colitis
CN108079206A (en) Alleviate decoction of nephrotic syndrome and preparation method thereof
CN102772548B (en) A kind of preparation method for the treatment of the Chinese medicine composition of lupus erythematosus
CN1994415B (en) Orally administered Chinese medicine for treating dysmenorrhea
CN101623493A (en) Herba artemisiae scopariae turtle shell soup for treating liver cirrhosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant